NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study in Healthy Adults Evaluating PF-07202954

CompletedPhase 1

Sponsor: Pfizer

Conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis

Interventions: PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo

Countries: United States

The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:- healthy subjects (all 3 Parts)

* evidence of steatosis on FibroScan (Part 2 only)
* BMI 17.5 to 30.5 kg/m2 (Part 1, Part 3)
* BMI 17.5 to 35.4 kg/m2 (Part 2) Exclusion Criteria:- evidence of clinically significant disease
* subjects on chronic medications
* clinically significant, abnormal laboratory results, vital signs, or cardiac conduction abnormalities
* contraindication to MRI (Part 2, only)

Locations (1)

New Haven, Connecticut, United States